1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Hikma Sharpens Focus On COVID-19 Demand

Maintains Financial Guidance Amid Coronavirus Challenges And Uncertainty

 
• By Dave Wallace

Hikma says it is prioritizing the production and delivery of medicines that are in the highest demand amid the COVID-19 pandemic, as the firm has provided a trading update that maintains its sales forecasts in the face of “challenging market conditions” and uncertainty.

Demand
Hikma is focused on meeting the highest demand amid the coronavirus pandemic • Source: Shutterstock

Hikma says it has made a strong start to 2020 across all three of its business segments – comprising injectables; non-injectable generics and specialty in the US; and the Middle East and North Africa branded segment – as it prioritizes the supply of medicines that are most in demand amid the COVID-19 pandemic.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

Despite Multiple Headwinds, Formycon Remains Positive For Its Biosimilars Growth

 
• By Urtė Fultinavičiūtė

Partnering opportunities, paused marketing, approvals, litigations, and many more. Formycon sets out the agenda for 2025, after seeing a bumpy start to the year.

Teva Crib Sheet Reveals Uzedy, Lenalidomide Expectations Ahead Of Q1

 
• By Dean Rudge

Teva is charting a new course under its ‘Pivot to Growth’ strategy, providing a memory aid for investors to better understand the firm’s financials going into 2025.

Alvotech Reveals Ramp-Up In Development As Sales Explode In 2024

 
• By Dave Wallace

With sales and profits shooting up in 2024, Alvotech has revealed plans to rapidly accelerate development to add between four and six programs to its pipeline of biosimilars every year, while at the same time unveiling details of several new brands that it will be seeking to challenge. The firm has also set out longer-term financial targets that anticipate more than trebling its revenues in the next three years.

Henlius Builds Profitability Streak With Second Year In The Black

 
• By Adam Zamecnik

The Chinese player reported its second profitable year in a row, with growth in sales reported across its marketed portfolio and further milestones in the near future.

More from Business

Aurobindo Plots Rivaroxaban Roll-Out As FDA Approves 2.5mg Strength ANDA

 
• By Dean Rudge

Aurobindo is set to join Lupin by competing against Johnson/Bayer’s blockbuster blood thinner Xarelto (rivaroxaban) 2.5mg tablets.

Coherus Marks Exit From Biosimilars By Completing Udenyca Divestment

 
• By Dave Wallace

Coherus has officially marked its exit from biosimilars by completing the divestment of its Udenyca pegfilgrastim franchise. Meanwhile, buyer Accord BioPharma has set out how it expects to benefit not only from a growing asset but also from the Coherus personnel that have moved over.

Wockhardt Confirms US Market Exit After Past Challenges

 
• By Adam Zamecnik

Following past challenges on the US market, the Indian pharma player Wockhardt will be shuttering its presence in the country due to commercial reasons.